CY1109281T1 - Μεθοδος ανιχνευσης παθογονου μικροοργανισμου και αντιμικροβιακου παραγοντα, μεθοδος αξιολογησης του αποτελεσματος φαρμακου των αντιμικροβιακων παραγοντων και αντιμικροβιακοι παραγοντες - Google Patents

Μεθοδος ανιχνευσης παθογονου μικροοργανισμου και αντιμικροβιακου παραγοντα, μεθοδος αξιολογησης του αποτελεσματος φαρμακου των αντιμικροβιακων παραγοντων και αντιμικροβιακοι παραγοντες

Info

Publication number
CY1109281T1
CY1109281T1 CY20091100847T CY091100847T CY1109281T1 CY 1109281 T1 CY1109281 T1 CY 1109281T1 CY 20091100847 T CY20091100847 T CY 20091100847T CY 091100847 T CY091100847 T CY 091100847T CY 1109281 T1 CY1109281 T1 CY 1109281T1
Authority
CY
Cyprus
Prior art keywords
pathogenic microorganism
antimicrobial
effect
antimicrobial agent
evaluation
Prior art date
Application number
CY20091100847T
Other languages
English (en)
Inventor
Yoshiyuki Tatsumi
Mamoru Yokoo
Kosho Nakamura
Tadashi Arika
Original Assignee
Kaken Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16654658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109281(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kaken Pharmaceutical Co., Ltd filed Critical Kaken Pharmaceutical Co., Ltd
Publication of CY1109281T1 publication Critical patent/CY1109281T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Μια νέα μέθοδος για αξιολόγηση αποτελέσματος ενός αντιμικροβιακού παράγοντα που περιλαμβάνει απομάκρυνση του αντι-μικροβιακού παράγοντα που παραμένει σε ένα βιολογικό δείγμα ή τα παρόμοια για να αξιολογηθεί επακριβώς με τον τρόπο αυτό το αποτέλεσμα του αντι-μικροβιακού παράγοντα χωρίς να επηρεάζεται από τον απομένοντα αντι-μικροβιακό παράγοντα. Ένας θεραπευτικός παράγων για ονυχομύκωση μπορεί να ληφθεί σύμφωνα με τη μέθοδο αξιολόγησης του αποτελέσματος φαρμάκου.
CY20091100847T 1999-07-28 2009-08-10 Μεθοδος ανιχνευσης παθογονου μικροοργανισμου και αντιμικροβιακου παραγοντα, μεθοδος αξιολογησης του αποτελεσματος φαρμακου των αντιμικροβιακων παραγοντων και αντιμικροβιακοι παραγοντες CY1109281T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21436999 1999-07-28
EP00944390A EP1205559B1 (en) 1999-07-28 2000-07-11 Method for detecting pathogenic microorganisms and antimicrobial agents, method for evaluating the drug effect of antimicrobial agents, and antimicrobial agents

Publications (1)

Publication Number Publication Date
CY1109281T1 true CY1109281T1 (el) 2014-07-02

Family

ID=16654658

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100847T CY1109281T1 (el) 1999-07-28 2009-08-10 Μεθοδος ανιχνευσης παθογονου μικροοργανισμου και αντιμικροβιακου παραγοντα, μεθοδος αξιολογησης του αποτελεσματος φαρμακου των αντιμικροβιακων παραγοντων και αντιμικροβιακοι παραγοντες

Country Status (12)

Country Link
US (2) US7214506B2 (el)
EP (2) EP1205559B1 (el)
JP (2) JP4414623B2 (el)
AT (1) ATE434667T1 (el)
AU (1) AU5852400A (el)
CA (1) CA2391274C (el)
CY (1) CY1109281T1 (el)
DE (1) DE60042453D1 (el)
DK (1) DK1205559T3 (el)
ES (1) ES2328785T3 (el)
PT (1) PT1205559E (el)
WO (1) WO2001007643A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013862A1 (en) * 2004-07-19 2006-01-19 Held Jerry M Onychomycosis: a new process for cure
JP4824493B2 (ja) * 2005-08-31 2011-11-30 株式会社ポーラファルマ 抗真菌剤の評価法
US8889155B2 (en) 2006-12-28 2014-11-18 Kaken Pharmaceutical Co., Ltd. Gel composition for treating mycosis
WO2009081976A1 (ja) * 2007-12-25 2009-07-02 Pola Pharma Inc. 微生物感染症の動物感染モデル
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
SG10201502900PA (en) * 2010-04-16 2015-06-29 Zeus Scientific Inc Methods for measuring enzyme activity useful in determining cell viability in non-purified samples
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
MY179756A (en) 2013-10-03 2020-11-12 Dow Pharmaceutical Sciences Stabilized efinaconazole formulations
CN105848719A (zh) 2013-11-22 2016-08-10 道尔医药科学公司 抗感染的方法、组合物和装置
AU2015379251A1 (en) * 2015-01-20 2017-07-27 Wavelength Enterprises Ltd Crystalline forms of efinaconazole
KR102060546B1 (ko) 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
JP7440073B2 (ja) * 2020-07-30 2024-02-28 国立大学法人広島大学 生存細菌の検出方法及びそのためのキット
KR20220150829A (ko) 2021-05-04 2022-11-11 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233502A (en) * 1989-06-09 1991-11-26 Janssen Pharmaceutica Nv 4-(1,2,4-triazole- or imidazole-phenyl-substituted) -1-(1,3-dioxolan-4-ylmethoxyphenyl) piperazine derivatives; preparatory processes: fungicidal and antiviral compositions
ES2110749T3 (es) * 1993-05-10 1998-02-16 Kaken Pharma Co Ltd Derivado de azolilamina.
JPH09504176A (ja) * 1993-10-25 1997-04-28 ライボジーン、インコーポレイテッド 抗真菌剤の選抜法
JP3404152B2 (ja) * 1994-10-04 2003-05-06 ポーラ化成工業株式会社 抗真菌剤の評価法
JP3129662B2 (ja) * 1996-07-16 2001-01-31 グンゼ株式会社 皮膚刺激判定法
PT983037E (pt) * 1998-02-09 2003-09-30 Macrochem Corp Verniz para unhas antifungico

Also Published As

Publication number Publication date
EP2112228A1 (en) 2009-10-28
JP2010004893A (ja) 2010-01-14
WO2001007643A1 (fr) 2001-02-01
JP4414623B2 (ja) 2010-02-10
EP1205559A4 (en) 2004-11-17
EP1205559A1 (en) 2002-05-15
CA2391274C (en) 2010-12-14
ATE434667T1 (de) 2009-07-15
PT1205559E (pt) 2009-08-04
CA2391274A1 (en) 2001-02-01
US7214506B2 (en) 2007-05-08
DE60042453D1 (de) 2009-08-06
US20070082375A1 (en) 2007-04-12
ES2328785T3 (es) 2009-11-18
DK1205559T3 (da) 2009-09-28
AU5852400A (en) 2001-02-13
US20080003636A1 (en) 2008-01-03
EP1205559B1 (en) 2009-06-24

Similar Documents

Publication Publication Date Title
CY1109281T1 (el) Μεθοδος ανιχνευσης παθογονου μικροοργανισμου και αντιμικροβιακου παραγοντα, μεθοδος αξιολογησης του αποτελεσματος φαρμακου των αντιμικροβιακων παραγοντων και αντιμικροβιακοι παραγοντες
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
DE50107049D1 (de) Sensor-anordnung und verfahren zum erfassen eines zustands eines transistors einer sensor-anordnung
ATE385259T1 (de) Verfahren zum nachweis von influenza a/b-viren in speichel
ES2082217T3 (es) Procedimiento de amplificacion de la señal de emision de un compuesto luminiscente.
ID27343A (id) Klon-klon infeksi virus penyakit newcastle, vaksin dan pengujian diagnostik
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
ATE330038T1 (de) Nukleinsäure-biosensor
BR122018068138B8 (pt) Amidas de ácido 3-aril-3-hidróxi-2-amino-propiônico, 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados tendo atividade analgésica e/ou imunoestimulante
PT1198713E (pt) Deteccao e identificacao de estirpes bacterianas
ATE335513T1 (de) Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene
WO2004027020A3 (en) Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
BRPI0519381A2 (pt) bactÉria atenuada viva de pasteurella multocida, vacina atenuada viva para a proteÇço de animais ou humanos contra infecÇço por pasteurella multocida ou seu efeitos patogÊnicos, uso de uma bactÉria atenuada viva, mÉtodo para a preparaÇço de uma vacina, e, teste diagnàstico para a detecÇço de dna ou rna associado com pasteurella multocida
EA200001197A1 (ru) Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина
CY1112063T1 (el) Παραγοντας κατα του ιου της νοσου του αφθωδους πυρετου για ζωα που ανηκουν στην οικογενεια των συιδων ή των προβατων, και μεθοδος για προληψη ή αντιμετωπιση της νοσου του αφθωδους πυρετου σε ζωα που ανηκουν στην οικογενεια των συιδων ή των προβατων
AR041713A1 (es) Una composicoin farmaceutica de duracion prolongada
DK1504088T3 (da) Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner
AR058959A1 (es) Metodos para modular receptores de la superficie celular para prevenir o reducir la inmflamacion
DE602004029194D1 (de) Methode zur messung der spezifizitat aktivierter lymphozyten
DE60109581D1 (de) Verfahren zur evaluierung von inplantierbaren materialien
DE50306224D1 (de) Markersubstanzen und ihre verwendung in diagnoseverfahren
DK1253961T4 (da) Detekterbare rustfrie nåle til ködemballering
WO2002017969A3 (en) Reagents and methods for the diagnosis of cmv dissemination
DE60005832D1 (de) Verfahren zum nachweis von mastitis
DK1307537T3 (da) Neospora caninum-isolat